glp-1 receptor agonist antipsychotic weight gain study Treatment of antipsychotic-associated obesity with a agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO protocol Graphical presentation of the mechanism
Description
Data Sources: Income: Median per capita annual income by state was sourced from the U.S
In 2005, the U.S
Over the last few years, GLP-1 medications have been approved with indications strictly for weight loss and chronic weight management by the U.S
Finkle and Brost, 2025
Endocrinology 154 , 24812488 (2013)
Seino Y, Fukushima M, Yabe D, Seino Y, Fukushima M, Yabe D
